CSF-based biomarkers for AD have been identified including CSF Aβ and tau–these are now used alongside cognitive and imaging biomarkers when diagnosing clinically probable AD (Dubois et al., 2014). The gene discussed is MAPT; the disease is Alzheimer disease.